Description: Anti-Asthmatic, Interleukin-5 Receptor Antagonist
CSA NA – FDA Approved – REMS (N) – Can Ship
How Does It Work
Benralizumab, Fasenra is a monoclonal antibody (IgG1, kappa) that binds to the alpha subunit of the interleukin-5 receptor. IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils (a cell type associated with inflammation and an important component in the pathogenesis of asthma). Benralizumab, Fasenra by inhibiting IL-5 signaling, reduces the production and survival of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity.
Indications For Use
Before starting Benralizumab, Fasenra makes sure your physician is aware of any allergies or medications you currently take. Benralizumab, Fasenra should never be used for acute asthmatic symptoms or exacerbations. Do not abruptly discontinue corticosteroids when initiating Benralizumab, Fasenra as they should be tapered off gradually if appropriate.
Subcutaneous Injection: 30mg every 4 weeks for the first 3 doses, then once every 8 weeks.
Pharmacist Tips On Using
How to Take: Prior to administration, allow syringe/autoinjector to warm at room temperature for ~30 minutes. Administer the subcutaneous injection into the upper arm, thigh, or abdomen. The prefilled syringe should only be administered by a health care provider; autoinjector may be administered by patient or caregiver after proper training. Refer to the manufacturer’s labeling for additional administration instructions.
Antibody development, headache, pharyngitis, fever.
Note this is not a complete list of side effects for Benralizumab, Faserna only common ones.
Frequently Asked Questions
What do I do if I have breakthrough symptoms?
Your rescue inhaler which is usually salbutamol should still be carried and used for any breakthrough symptoms as prescribed. Benralizumab may eventually replace inhaled corticosteroid and is intended to reduce exacerbations but is not used as a rescue medication.